U.S. markets open in 6 hours 41 minutes

Ocuphire Pharma, Inc. (OCUP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.2000-0.1100 (-2.55%)
At close: 4:00PM EDT

Ocuphire Pharma, Inc.

37000 Grand River Avenue
Suite 120
Farmington Hills, MI 48335
United States
248 681 9815
http://www.ocuphire.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees5

Key Executives

NameTitlePayExercisedYear Born
Ms. Mina Patel Sooch M.B.A., MBAFounder, CEO, Pres, Treasurer & Vice Chair of the Board112.79kN/A1968
Ms. Amy Zaremba Rabourn C.P.A., MAcc, CPAVP of Fin. & Principal Accounting Officer53.03kN/A1980
Mr. Bernhard Hoffmann M.B.A.VP of Corp. Devel. & Operations and Sec.45.01kN/A1956
Dr. Daniela Oniciu Ph.D.Head of CMC and Global Clinical Supply ManufacturingN/AN/AN/A
Dr. Mitchell BrigellHead of Clinical Devel. & StrategyN/AN/AN/A
Ms. Drey ColemanHead of Clinical OperationsN/AN/AN/A
Mr. Erik SimsDirector & Corp. ControllerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.

Corporate Governance

Ocuphire Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.